^
Association details:
| Biomarker: | ETV6 amplification |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Published date:
01/25/2021
Excerpt:
...patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression or unacceptable toxicity....Whole-exome sequencing results from 174 patients revealed that the patients with genomic amplification in 11q13 region or ETV6 genomic alterations had poor responses to toripalimab.
DOI:
10.1200/JCO.20.02712
Trial ID:
